What is the prevalence of systemic lupus erythematosus?

Prevalence of Systemic Lupus Erythematosus

The global prevalence of systemic lupus erythematosus is approximately 43.7 per 100,000 persons (ranging from 15.87 to 108.92), affecting an estimated 3.41 million people worldwide, with substantial geographic, racial, and sex-based variation. 1

Global and Regional Estimates

The prevalence of SLE varies dramatically by geographic location and demonstrates a clear upward trend over recent decades:

• United States: The pooled prevalence is 72.8 per 100,000 persons (95% CI 65.3-81.0), translating to approximately 204,295 individuals affected in 2018 2
• United Kingdom: Point prevalence increased fivefold from 21.4 per 100,000 in 1990 to 107.14 per 100,000 in 2020, despite stable or slightly declining incidence rates 3
• Highest prevalence regions: The United Arab Emirates, Barbados, and Brazil demonstrate the highest prevalence estimates globally 1

Sex-Based Disparities

SLE demonstrates a profound female predominance across all populations:

• Women: Global prevalence of 78.73 per 100,000 (28.61 to 196.33), affecting approximately 3.04 million women worldwide 1
• Men: Global prevalence of 9.26 per 100,000 (3.36 to 22.97), affecting approximately 0.36 million men worldwide 1
• Female-to-male ratio: Approximately 8-10:1 across most populations 4, 2

In the United States specifically, the prevalence among females is 128.7 per 100,000 compared to 14.6 per 100,000 among males 2

Racial and Ethnic Disparities

Racial and ethnic minorities bear a disproportionate burden of SLE, with both higher prevalence and more severe disease manifestations 4:

United States Racial/Ethnic Prevalence (per 100,000):

• Black females: 230.9 (highest among all groups) 2
• American Indian/Alaska Native females: 270.6 2
• Hispanic females: 120.7 2
• Asian/Pacific Islander females: 84.4 2
• White females: 84.7 2

Among males, similar disparities exist with Black males (26.7 per 100,000) and American Indian/Alaska Native males (53.8 per 100,000) showing the highest prevalence 2

Clinical Implications of Racial Disparities:

Latin American, African-descended, and Native American patients experience 4:

• Earlier age at diagnosis
• More severe disease manifestations
• Higher disease activity levels
• Greater organ damage accumulation
• Higher mortality rates, primarily from disease activity and infections

In Michigan, Black patients demonstrated 2.3-fold higher prevalence than White patients, with 40.5% developing renal disease compared to 18.8% in White patients, and progression to end-stage renal disease occurring in 15.3% versus 4.5% respectively 5

Temporal Trends

SLE prevalence is increasing substantially over time, while incidence rates remain relatively stable or show modest increases 3, 6:

• A US population study showed incidence rising from 3.32 per 100,000 during 1976-1988 to 6.44 per 100,000 during 2009-2018 6
• The fivefold increase in UK prevalence over 30 years (1990-2020) in the context of stable incidence suggests improved survival and disease management 3
• This divergence between rising prevalence and stable incidence has critical implications for healthcare resource allocation and long-term care planning 3

Incidence Data

For context, the global annual incidence is estimated at 5.14 per 100,000 person-years (1.4 to 15.13), with approximately 0.40 million new cases diagnosed annually worldwide 1:

• Female incidence: 8.82 per 100,000 person-years 1
• Male incidence: 1.53 per 100,000 person-years 1
• US overall incidence: 5.5 per 100,000 person-years (95% CI 5.0-6.1) 5

Clinical Context

The estimated prevalence range of 20 to 150 cases per 100,000 population cited in earlier literature 4 aligns with contemporary data showing substantial geographic variation. The disease predominantly affects women of childbearing age, with clinical heterogeneity ranging from mild mucocutaneous manifestations to life-threatening multi-organ involvement 4

Important caveat: Epidemiological data on SLE are lacking for 79.8% of countries worldwide, meaning true global burden may be underestimated, particularly in low- and middle-income countries 1